Related Experiment Video
Updated: Jan 13, 2026

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
Published on: August 25, 2022
Mpox therapeutics in the post-STOMP/PALM era.
Katherine Promer1, Sara Bt Brenner, Lily Ostrer
1Department of Medicine, Division of Infectious Diseases and Global Public Health University of California San Diego, San Diego, California, USA.
Current mpox antiviral therapies, including tecovirimat, lack demonstrated clinical efficacy. Further research is needed to establish effective treatments for mpox virus infections.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Mpox (monkeypox) is a viral disease that has seen increased global outbreaks.
- Antiviral therapies have been explored for mpox treatment, with tecovirimat widely used compassionately.
Purpose of the Study:
- To review the clinical evidence for available and investigational mpox antiviral therapies.
- To assess the efficacy of tecovirimat and other treatments for mpox.
Main Methods:
- Systematic review of clinical trial data.
- Analysis of evidence for tecovirimat, brincidofovir, cidofovir, trifluridine, and VIGIV.
Main Results:
- Phase 3 placebo-controlled trials show tecovirimat lacks clinical efficacy in treating mpox.
- Evidence for other antivirals and VIGIV is summarized.
Conclusions:
- Tecovirimat's clinical efficacy for mpox is not supported by current evidence.
- A summary of evidence for various mpox treatments is provided, highlighting the need for effective therapies.
More Related Videos
08:55Use of a Foot-Induced Digitally Controlled Resistance Device for Functional Magnetic Resonance Imaging Evaluation in Patients with Foot Paresis
Published on: July 7, 2023
12:42Photoactivated Localization Microscopy with Bimolecular Fluorescence Complementation BiFC-PALM
Published on: December 22, 2015
Related Concept Videos
Peripheral Artery Disease I: Introduction
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
PPE Use in Healthcare Settings I: Donning
Preclinical Development: Overview
Olefin Metathesis Polymerization: Ring-Opening Metathesis Polymerization (ROMP)
Peripheral Artery Disease III: Interprofessional Care